Abstract 2978
Background
Cancer and diabetes are prevalent diseases worldwide. The purpose of this study was to assess quality of life and the factors influence it in the individuals with coexistence diabetes type 2 and cancer.
Methods
A cross-sectional study was conducted in a large hospital in a major Greek city. Convenience sample of 101 patients with cancer and diabetes type 2 undergoing chemotherapy constituted the study group. Quality of life was measured by the Audit of Diabetes Depedent-QoL-Questionnaire (ADDQoL-19). Information on social-demographic, treatment of tumors and diabetes, and other clinical characteristics were collected by other questionnaire. Descriptive statistics were used for demographic characteristics. For data that were not normally distributed, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis test) were applied.
Results
The majority of patients had cancer stage II (n = 52, 51,5%) and diabetes 2 for almost seven years. Individuals with coexistence of diabetes 2 and cancer reported that disease affected the overall quality of life (1.84±1.18). Also, there is a negative score in other subscale as freedom to eat (-1.43 ±0.80) and financial situation (-1.25±0,84). It was found that cancer’s stage influences the general quality of life domain (p = 0.023). Also, there were statistical significant differences between type of regimen for diabetes and several domains of quality of life. More particular, working life (p = 0.004), family life (p = 0.003), friendship and social life (p = 0.005), physical health (p = 0.003), leisure activities (p = 0.004) and financial situation (p = 0.004) are some of these domains that they are further influenced. Additionally the family status influences self-confidence (p = 0.001) and motivation (p = 0.007).
Conclusions
Taking all the above under consideration, we conclude that social-demographic and clinical characteristics were associated with quality of life in patients with cancer and diabetes 2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2607 - Single cycle induction treatment with Cisplatin/Docetaxel plus Durvalumab/Tremelimumab in Stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)
Presenter: Markus Hecht
Session: Poster Display session 3
Resources:
Abstract
1388 - Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dillema finally resolved. An updated meta-analysis.
Presenter: Petar Suton
Session: Poster Display session 3
Resources:
Abstract
1478 - Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations.
Presenter: Majd Issa
Session: Poster Display session 3
Resources:
Abstract
3985 - Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Presenter: Jovian Yu
Session: Poster Display session 3
Resources:
Abstract
4036 - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: study PANTERA
Presenter: Javier Martinez Trufero
Session: Poster Display session 3
Resources:
Abstract
4779 - Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (SCCHN): interim safety analysis
Presenter: Tony Richa
Session: Poster Display session 3
Resources:
Abstract
2757 - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)
Presenter: Suraj Singh
Session: Poster Display session 3
Resources:
Abstract
5559 - Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck
Presenter: Sanket Shukla
Session: Poster Display session 3
Resources:
Abstract
3263 - Risk and Impact of Renal Impairment of Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Who Received Chemoradiotherapy with Cisplatin
Presenter: Thana Patimarattananan
Session: Poster Display session 3
Resources:
Abstract
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract